Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.40 |
| ▸ | KDM7A | Q6ZMT4 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 11/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25183111 | 0.88 | ALDH1A1 (0.48) | ALDH1A1PHF8KDM2AKDM7ACHRNB2 | |
| SCHEMBL31369528 | 0.86 | ALDH1A1 (0.47) | ALDH1A1PHF8KDM2AKDM7ACHRNB2 | |
| SCHEMBL7429240 | 0.80 | PHF8 (0.35) | ALDH1A1PHF8KDM2AKDM7AKDM4C | |
| SCHEMBL158810 | 0.78 | LMNA (0.47) | PHF8KDM2AKDM6BKDM5CEGLN1 | |
| SCHEMBL322794 | 0.76 | PHF8 (0.64) | ALDH1A1PHF8KDM2AKDM7ACHRNB2 | |
| Hydrochloric Acid SCHEMBL28658324 | 0.76 | LMNA (0.44) | PHF8KDM2AKDM6BKDM5CEGLN1 | |
| SCHEMBL8186348 | 0.76 | LMNA (0.44) | PHF8KDM2AKDM6BKDM5CEGLN1 | |
| SCHEMBL19705578 | 0.76 | ALDH1A1 (0.43) | ALDH1A1CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL4616554 | 0.76 | ALDH1A1 (0.54) | ALDH1A1CHRNB2CHRNB4CHRNA4KDM4C | |
| SCHEMBL7049362 | 0.75 | KDM4C (0.39) | PHF8KDM2AKDM7AKDM4AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-3769786-A1 | ANTIBODY-DRUG CONJUGATE HAVING ACIDIC SELF-STABILIZATION JUNCTION | Sichuan Baili Pharm Co. Ltd (CN) | 2021-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | ALDH1A1 4472/4885PHF8 4629/4885KDM2A 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.